As October marks Breast Cancer Awareness Month, a spotlight is cast on the continuing challenge of breast cancer, the most common cancer in the United States and the leading cause of cancer deaths among women.
In 2024, the American Cancer Society (ACS) estimates that over 310,720 new cases of invasive breast cancer, along with 56,500 new cases of ductal carcinoma in situ (stage 0 breast cancer), will be diagnosed in women nationwide. Despite significant progress in reducing breast cancer deaths by 42 percent over the past 30 years—thanks to heightened awareness, earlier detection, and more effective treatments—startling disparities persist, particularly among Black women.
Data from the ACS reveal that while the disease incidence rates are comparable between Black and white women, mortality rates differ dramatically. Black women face a staggering 40 percent higher death rate from breast cancer. Among younger women, the disparity is even greater, with young Black women experiencing double the mortality rate of their white counterparts, often due to more aggressive cancer types.
These disparities arise from a complex interplay of social, economic, geographic, and lifestyle factors. Statistically, Black women are more likely to have comorbidities such as diabetes, heart disease, and obesity—conditions that increase risk. Additionally, many Black women encounter barriers to adequate healthcare access and insurance coverage, impacting their ability to receive timely screenings and effective treatment.
Research indicates that biological factors also contribute to these disparities. Black women are disproportionately affected by aggressive breast cancer subtypes like triple-negative breast cancer (TNBC) and inflammatory breast cancer, and they are often diagnosed at younger ages and later stages of the disease, which complicates treatment outcomes.
Results from prominent clinical trials, including TAILORx and RxPONDER, have identified significant differences in breast cancer recurrence and outcomes based on race. Dr. Joseph Sparano, a lead investigator on the TAILORx trial, reported that while late recurrences were common across all participants, early recurrences showed marked disparities. The RxPONDER study found that Black women with HR-positive/HER2-negative, lymph node-positive breast cancer had poorer outcomes compared to women from other racial and ethnic groups, despite similar recurrence scores. Additionally, tumors in Black women may respond differently to endocrine therapy and are more prone to developing resistance.
A 2017 study highlighted that four key factors accounted for 76.3 percent of the excess mortality risk in Black women diagnosed with early-stage breast cancer. These included a lack of private health insurance (37 percent), tumor characteristics (23.2 percent), comorbidities (11.3 percent), and treatment differences (4.8 percent). Furthermore, research led by Dr. Marianna Chavez MacGregor demonstrated that in states expanding Medicaid under the Affordable Care Act, survival disparities between white women and other racial/ethnic groups with stage 4 breast cancer were eliminated.
To combat these disparities, the National Cancer Institute suggests several strategies, such as creating statewide cancer screening programs accessible to underserved populations and addressing biological differences in the disease across racial and ethnic groups. Cities that have successfully enhanced access to advanced mammography facilities have reported notable progress in narrowing the mortality gap between Black and white women.
As we reflect on the complexities of the disease this October, the phrase “every woman’s breast cancer is unique” serves as a powerful reminder of the need for personalized approaches in treatment and research. While significant advances have been made in understanding the molecular drivers of the disease, most studies and clinical trials predominantly involve white women. Expanding participation among Black women in research is essential for tailoring effective treatments and improving outcomes for all women affected by this disease.
As we advance through Breast Cancer Awareness Month, it is crucial to recognize and address these disparities, ensuring equitable access to care and fostering a future where all women, regardless of race or socioeconomic status, have the opportunity for better health outcomes in the fight against the disease.
This information is based on research from the Breast Cancer Research Foundation.
